Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David R Guyer

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Clinical & Experimental Ophthalmology|July 26, 2003
Age-dependent variations in the drusen fluorescence on indocyanine green angiographyAndrew A Chang, David R Guyer, Dennis R Orlock, et al.
Retina (Philadelphia, Pa.)|July 29, 2005
Histopathologic features of idiopathic macular holes and cysts. 1990David R Guyer, W Richard Green, Serge de Bustros, et al.
The New England Journal of Medicine|December 31, 2004
Pegaptanib for neovascular age-related macular degenerationEvangelos S Gragoudas, Anthony P Adamis, Emmett T Cunningham, et al.
Ophthalmology Clinics of North America|January 8, 2003
Antiangiogenesis agentsAntonio P Ciardella, Irene M Donsoff, David R Guyer, et al.
Retina (Philadelphia, Pa.)|March 28, 2012
Digital indocyanine green videoangiography and choroidal neovascularization. 1992Lawrence A Yannuzzi, Jason S Slakter, John A Sorenson, et al.
American Journal of Ophthalmology|June 6, 2003
Optical coherence tomography findings in nicotinic acid maculopathyMarc J Spirn, Floyd A Warren, David R Guyer, et al.
Archives of Ophthalmology (Chicago, Ill. : 1960)|July 14, 2004
Accelerated drug development through combined phase 2/3 clinical trial designEmmett T Cunningham, Loni da Silva, Evelyn M Harrison, et al.
Nature Reviews. Drug Discovery|March 7, 2006
Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular diseaseEugene W M Ng, David T Shima, Perry Calias, et al.
American Journal of Ophthalmology|July 4, 2002
Treatment of idiopathic subfoveal choroidal neovascular lesions using photodynamic therapy with verteporfinRichard F Spaide, Melissa L Martin, Jason Slakter, et al.
Ophthalmology|December 14, 2005
Changes in retinal neovascularization after pegaptanib (Macugen) therapy in diabetic individualsAnthony P Adamis, Michael Altaweel, Neil M Bressler, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Clinical & Experimental Ophthalmology|July 26, 2003
Age-dependent variations in the drusen fluorescence on indocyanine green angiographyAndrew A Chang, David R Guyer, Dennis R Orlock, et al.
Retina (Philadelphia, Pa.)|July 29, 2005
Histopathologic features of idiopathic macular holes and cysts. 1990David R Guyer, W Richard Green, Serge de Bustros, et al.
The New England Journal of Medicine|December 31, 2004
Pegaptanib for neovascular age-related macular degenerationEvangelos S Gragoudas, Anthony P Adamis, Emmett T Cunningham, et al.
Ophthalmology Clinics of North America|January 8, 2003
Antiangiogenesis agentsAntonio P Ciardella, Irene M Donsoff, David R Guyer, et al.
Retina (Philadelphia, Pa.)|March 28, 2012
Digital indocyanine green videoangiography and choroidal neovascularization. 1992Lawrence A Yannuzzi, Jason S Slakter, John A Sorenson, et al.
American Journal of Ophthalmology|June 6, 2003
Optical coherence tomography findings in nicotinic acid maculopathyMarc J Spirn, Floyd A Warren, David R Guyer, et al.
Archives of Ophthalmology (Chicago, Ill. : 1960)|July 14, 2004
Accelerated drug development through combined phase 2/3 clinical trial designEmmett T Cunningham, Loni da Silva, Evelyn M Harrison, et al.
Nature Reviews. Drug Discovery|March 7, 2006
Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular diseaseEugene W M Ng, David T Shima, Perry Calias, et al.
American Journal of Ophthalmology|July 4, 2002
Treatment of idiopathic subfoveal choroidal neovascular lesions using photodynamic therapy with verteporfinRichard F Spaide, Melissa L Martin, Jason Slakter, et al.
Ophthalmology|December 14, 2005
Changes in retinal neovascularization after pegaptanib (Macugen) therapy in diabetic individualsAnthony P Adamis, Michael Altaweel, Neil M Bressler, et al.
Pageof 2